TY - JOUR
T1 - Is cross-femoral bypass grafting a disadvantage of aortomonoiliac endovascular aortic aneurysm repair?
AU - Yilmaz, Lâl P.K.
AU - Abraham, Cherrie Z.
AU - Reilly, Linda M.
AU - Gordon, Roy L.
AU - Schneider, Darren B.
AU - Messina, Louis M.
AU - Chuter, Timothy A.M.
PY - 2003/10
Y1 - 2003/10
N2 - Purpose: The need for cross-femoral bypass grafting (CFBG) is considered by some to be a major disadvantage of endovascular aneurysm repair (EVAR) with the aortomonoiliac technique. To determine the durability of CFBG in this setting, we examined data from 148 consecutive high-risk patients in a clinical trial of EVAR with a custom-made aortomonoiliac endovascular stent graft. Methods: All data were collected prospectively. After hospital discharge, patients were evaluated at 1, 3, and 6 months and annually thereafter. All CFBG was constructed of expandable polytetrafluoroethylene. Results: During follow-up averaging 23.6 ± 16.2 months, nine CFBG complications developed in 8 patients (5.4%), including disruption (n = 2), infection (n = 3), thrombosis (n = 2), and pseudoaneurysm (n = 3). Four patients with CFBG complications died, of consequences of infection (n = 2), intracranial hemorrhage during attempted CFBG thrombolysis (n = 1), and intracranial hemorrhage during anticoagulation (n = 1). There were no amputations. At life table analysis, freedom from CFBG complication was 96.3% ± 1.6% at 12 months, 94.1% ± 2.2% at 24, 36, and 48 months, and 86.2% ± 7.8% at 60 months. Overall survival for this high-risk patient group was 83.4% ± 3.1% at 12 months, 70.4% ± 4.1% at 24 months, 56.5% ± 5.3% at 36 months, and 44.8% ± 6.4% at 48 months. Conclusion: CFBG is durable, with a low rate of complications in patients undergoing aortomonoiliac EVAR. Need for CFBG should not discourage use of aortomonoiliac devices in patients with anatomy unfavorable for other EVAR approaches.
AB - Purpose: The need for cross-femoral bypass grafting (CFBG) is considered by some to be a major disadvantage of endovascular aneurysm repair (EVAR) with the aortomonoiliac technique. To determine the durability of CFBG in this setting, we examined data from 148 consecutive high-risk patients in a clinical trial of EVAR with a custom-made aortomonoiliac endovascular stent graft. Methods: All data were collected prospectively. After hospital discharge, patients were evaluated at 1, 3, and 6 months and annually thereafter. All CFBG was constructed of expandable polytetrafluoroethylene. Results: During follow-up averaging 23.6 ± 16.2 months, nine CFBG complications developed in 8 patients (5.4%), including disruption (n = 2), infection (n = 3), thrombosis (n = 2), and pseudoaneurysm (n = 3). Four patients with CFBG complications died, of consequences of infection (n = 2), intracranial hemorrhage during attempted CFBG thrombolysis (n = 1), and intracranial hemorrhage during anticoagulation (n = 1). There were no amputations. At life table analysis, freedom from CFBG complication was 96.3% ± 1.6% at 12 months, 94.1% ± 2.2% at 24, 36, and 48 months, and 86.2% ± 7.8% at 60 months. Overall survival for this high-risk patient group was 83.4% ± 3.1% at 12 months, 70.4% ± 4.1% at 24 months, 56.5% ± 5.3% at 36 months, and 44.8% ± 6.4% at 48 months. Conclusion: CFBG is durable, with a low rate of complications in patients undergoing aortomonoiliac EVAR. Need for CFBG should not discourage use of aortomonoiliac devices in patients with anatomy unfavorable for other EVAR approaches.
UR - http://www.scopus.com/inward/record.url?scp=0141885373&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0141885373&partnerID=8YFLogxK
U2 - 10.1016/S0741-5214(03)00721-3
DO - 10.1016/S0741-5214(03)00721-3
M3 - Article
C2 - 14560225
AN - SCOPUS:0141885373
SN - 0741-5214
VL - 38
SP - 753
EP - 757
JO - Journal of vascular surgery
JF - Journal of vascular surgery
IS - 4
ER -